Gosselies, Belgium - March 5, 2019 - iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that Michel Detheux, Ph.D., Chief Executive Officer of iTeos, will present in two upcoming U.S. conferences in March.
- Cowen & Company 39th Annual Health Care Conference on Tuesday, March 12, 2019 at 11:30 a.m. ET in Boston, MA.
- William Blair 9th Annual Cancer Immunotherapy Conference on Thursday, March 21, 2019 at 3:15 p.m. ET in New York, NY.
About iTeos Therapeutics
iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of persons living with cancer by designing and developing next generation immunotherapies. The Company's lead program, EOS100850, is a best in class adenosine A2A receptor antagonist currently in a Phase 1/1b study. A second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS884448), is expected to enter the clinic in second half of 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded through the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain). In 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, along with new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. Previous investors, including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit www.iteostherapeutics.com
For further information, please contact:
Michel Detheux, CEO
iTeos Therapeutics
Amber Fennell, Mathew Neal, Sukaina Virji, Hendrik Thys
Consilium Strategic Communications
+44 203 709 5700
Sarah McCabe and Carl Mauch
Stern Investor Relations, Inc.
+ 1 212 362 1200